−2.20NOK
−87.94 MNOK
3.99 MNOK
36.99 M
About LYTIX BIOPHARMA AS
Sector
CEO
Øystein Rekdal
Headquarters
Oslo
Website
Founded
2003
ISIN
NO0010405780
FIGI
BBG0118SWW28
Lytix Biopharma AS engages in the development of novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company was founded by Øystein Rekdal and John Sigurd Mjøen Svendsen in 2003 and is headquartered in Tromso, Norway.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of LYTIX is 5.40 NOK — it has increased by 0.75% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OSL exchange LYTIX BIOPHARMA AS stocks are traded under the ticker LYTIX.
LYTIX stock is 3.05% volatile and has beta coefficient of 1.02. Check out the list of the most volatile stocks — is LYTIX BIOPHARMA AS there?
Yes, you can track LYTIX BIOPHARMA AS financials in yearly and quarterly reports right on TradingView.
LYTIX stock has fallen by 1.82% compared to the previous week, the month change is a 15.63% fall, over the last year LYTIX BIOPHARMA AS has showed a 17.56% decrease.
LYTIX net income for the last quarter is −18.58 M NOK, while the quarter before that showed −18.25 M NOK of net income which accounts for −1.82% change. Track more LYTIX BIOPHARMA AS financial stats to get the full picture.
Today LYTIX BIOPHARMA AS has the market capitalization of 214.77 M, it has decreased by 3.81% over the last week.
No, LYTIX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, LYTIX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade LYTIX BIOPHARMA AS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So LYTIX BIOPHARMA AS technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating LYTIX BIOPHARMA AS stock shows the sell signal. See more of LYTIX BIOPHARMA AS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. LYTIX BIOPHARMA AS EBITDA is −103.07 M NOK, and current EBITDA margin is −2.58 K%. See more stats in LYTIX BIOPHARMA AS financial statements.